We use cookies to help provide you with the best possible online experience. By using this site, you agree that we may store and access cookies on your device. You can find out more about how to set your own preferences here.

Cerbios appoints Stefano Console as Director Commercial Business Development

April 01 2010

Cerbios-Pharma SA (from now on “Cerbios”) announced today that Stefano Console has joined as Director Commercial Business Development.

In this role, Mr. Console will be responsible for managing all aspects of the company's business development for the chemical services sector from the strategic, commercial and relationship management point-of-view.

Prior to joining Cerbios, Mr. Console was Business and Financial Director at Micro-Macinazione SA.

"We are pleased that Stefano has decided to join the Cerbios team to help us with our strategy to both grow our current business and to strengthen our commercial platform for the services provided in areas such as High Potency Active Ingredients," said Gabriel Haering, CEO. "Stefano brings a wealth of diverse experience in contract manufacturing for the pharmaceutical industry, which will be essential to Cerbios as we continue to expand our unique service platform and address the evolving challenges of this industry."

After five years spent in Process Development at two different pharmaceutical fine chemical companies, in 1998 he joined the world of third party chemical manufacturing as manager business development.

The broad experience gathered during the past twelve years with different contract manufacturers (including Zambon, Chemi and Flamma) covered strategic roles managing a large number of successful projects for big to small Pharma partners across EU, USA and Japan

Mr. Console received his degree in chemistry from the University of Milan.

Photo gallery

About Cerbios-Pharma SA

Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners world-wide.

Exclusive, third-party manufacturing services are offered by the Chemical Division for HPAIs and by the Biological Division for monoclonal antibodies, recombinant proteins and pharma probiotics.

Cerbios provides full CMC support to its world-wide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.